14:21:47 EST Mon 11 Nov 2019
Enter Symbol
or Name
USA
CA



Callitas Health Inc
Symbol LILY
Shares Issued 32,462,095
Close 2018-03-08 C$ 0.32
Recent Sedar Documents

Callitas has sperm selection patent allowance notice

2018-03-08 18:26 ET - News Release

Mr. James Thompson reports

CALLITAS HEALTH, INC RECEIVES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT APPLICATION FOR TREATMENT FOR MALE INFERTILITY AND SUB-FERTILITY

The U.S. Patent and Trademark Office (USPTO) has granted notice of allowance for Callitas Health Inc.'s patent application for in vivo sperm selection for treating male infertility. This patent notice of allowance expands the company's IP (intellectual property) portfolio and furthers the patent-protected formula, and uses of, the ToConceive product, allowing it to be used to treat male infertility (or subfertility) caused by a reduced number of normal, functional sperm in the male partner.

The granting of this additional patent by the USPTO advances the company's mission to help couples trying to conceive, whether they are dealing with male or female infertility or a combination of the two.

"Male infertility (or subfertility) does not receive the attention it should," said James Thompson, interim president and chief executive officer. "Statistics indicate that nearly two-thirds of all infertility challenges are linked back to the male partner, and can be heightened with a lack of lubrication from the woman.

"This patent notice of allowance helps strengthen the company's core intellectual property assets of the ToConceive brand and reinforces Callitas's commitment to female health and wellness," Mr. Thompson added. "Our ongoing work underscores the company's mission to helping couples with both female infertility and male infertility, for those trying to conceive."

Callitas plans to expand its intellectual property portfolio with additional divisional applications from this current grant, as well as additional patents in the female fertility and sexual wellness space.

About Callitas Health Inc.

Formed in early 2015, Callitas Health is a clinical-stage company developing innovative technologies for obesity, weight management, and female health and wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the company launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.